Cryptococcus neoformans Variants Generated by Phenotypic Switching Differ in Virulence through Effects on Macrophage Activation

ABSTRACT Macrophages have a central role in the pathogenesis of cryptococcosis since they are an important line of defense, serve as a site for fungal replication, and also can contribute to tissue damage. The objective of this study was to investigate the interaction of macrophages with cells from smooth-colony variants (SM) and mucoid-colony variants (MC) arising from phenotypic switching of Cryptococcus neoformans. Alveolar macrophages (AMs) isolated from SM- and MC-infected mice exhibited differences in gene and surface expression of PD-L1, PD-L2, and major histocompatibility class II (MHC-II). PD-L1 and PD-L2 are the ligands for PD1 and are differentially regulated in Th1- and Th2-type cells. In addition, macrophage activation in SM- and MC-infected mice was characterized as alternatively activated. Flow cytometric and cytokine analysis demonstrated that MC infection was associated with the emergence of Th17 cells and higher levels of interleukin-17 (IL-17) in lung tissue, which were reduced by AM depletion. In conclusion, our results indicate that macrophages play a significant role in maintaining damage-promoting inflammation in the lung during MC infection, which ultimately results in death.

[1]  Yanmei Zhang,et al.  Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99. , 2009, The American journal of pathology.

[2]  J. Heitman,et al.  Loss of Allergen 1 Confers a Hypervirulent Phenotype That Resembles Mucoid Switch Variants of Cryptococcus neoformans , 2008, Infection and Immunity.

[3]  Jianfei Yang,et al.  Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells , 2008, European journal of immunology.

[4]  A. Guerrero,et al.  Phenotypic Switching in Cryptococcus neoformans Contributes to Virulence by Changing the Immunological Host Response , 2008, Infection and Immunity.

[5]  F. Dromer,et al.  Cryptococcal Neuroradiological Lesions Correlate with Severity during Cryptococcal Meningoencephalitis in HIV-Positive Patients in the HAART Era , 2008, PloS one.

[6]  Gesine Hansen,et al.  IL-13 Induces Disease-Promoting Type 2 Cytokines, Alternatively Activated Macrophages and Allergic Inflammation during Pulmonary Infection of Mice with Cryptococcus neoformans1 , 2007, The Journal of Immunology.

[7]  Francesco Bistoni,et al.  IL‐23 and the Th17 pathway promote inflammation and impair antifungal immune resistance , 2007, European journal of immunology.

[8]  A. Casadevall,et al.  Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages , 2007, BMC Immunology.

[9]  J. Perfect,et al.  Fatty Acid Synthesis Is Essential for Survival of Cryptococcus neoformans and a Potential Fungicidal Target , 2007, Antimicrobial Agents and Chemotherapy.

[10]  A. Casadevall,et al.  Capsule Structural Heterogeneity and Antigenic Variation in Cryptococcus neoformans , 2007, Eukaryotic Cell.

[11]  P. De Baetselier,et al.  Alternatively activated macrophages in protozoan infections. , 2007, Current opinion in immunology.

[12]  W. Gause,et al.  Alternatively activated macrophages in helminth infections. , 2007, Current opinion in immunology.

[13]  J. Heitman,et al.  Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. , 2007, The Journal of infectious diseases.

[14]  A. Casadevall,et al.  Phagosome Extrusion and Host-Cell Survival after Cryptococcus neoformans Phagocytosis by Macrophages , 2006, Current Biology.

[15]  S. Levitz,et al.  In Vivo Role of Dendritic Cells in a Murine Model of Pulmonary Cryptococcosis , 2006, Infection and Immunity.

[16]  T. Mcclanahan,et al.  IL-23 Enhances the Inflammatory Cell Response in Cryptococcus neoformans Infection and Induces a Cytokine Pattern Distinct from IL-121 , 2006, The Journal of Immunology.

[17]  Vincent Ferretti,et al.  A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis , 2005, Nature Genetics.

[18]  P. Peixoto,et al.  Arginase I Induction during Leishmania major Infection Mediates the Development of Disease , 2005, Infection and Immunity.

[19]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[20]  A. Celada,et al.  Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  J. Erb-Downward,et al.  Role of IFN-γ in Regulating T2 Immunity and the Development of Alternatively Activated Macrophages during Allergic Bronchopulmonary Mycosis 1 , 2005, The Journal of Immunology.

[22]  A. Casadevall,et al.  Cryptococcus neoformans Capsular Glucuronoxylomannan Induces Expression of Fas Ligand in Macrophages1 , 2005, The Journal of Immunology.

[23]  D. Pietrella,et al.  Mannoproteins from Cryptococcus neoformans Promote Dendritic Cell Maturation and Activation , 2005, Infection and Immunity.

[24]  J. Erb-Downward,et al.  Distinct Roles for IL-4 and IL-10 in Regulating T2 Immunity during Allergic Bronchopulmonary Mycosis1 , 2005, The Journal of Immunology.

[25]  A. Casadevall,et al.  The damage-response framework of microbial pathogenesis , 2003, Nature Reviews Microbiology.

[26]  A. Casadevall,et al.  Phenotypic switching of Cryptococcus neoformans can influence the outcome of the human immune response , 2003, Cellular microbiology.

[27]  P. Loke,et al.  PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. Amankwah,et al.  Primary Dendritic Cells Phagocytose Cryptococcus neoformans via Mannose Receptors and Fcγ Receptor II for Presentation to T Lymphocytes , 2002, Infection and Immunity.

[29]  A. Casadevall,et al.  Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Casadevall,et al.  Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection. , 2001, The Journal of clinical investigation.

[31]  F. Bistoni,et al.  Interdependency of Interleukin-10 and Interleukin-12 in Regulation of T-Cell Differentiation and Effector Function of Monocytes in Response to Stimulation withCryptococcus neoformans , 2001, Infection and Immunity.

[32]  A. Casadevall,et al.  Host-pathogen interactions: the attributes of virulence. , 2001, The Journal of infectious diseases.

[33]  P. De Baetselier,et al.  Alternative versus classical macrophage activation during experimental African trypanosomosis. , 2001, Journal of leukocyte biology.

[34]  V. Iniesta,et al.  The Inhibition of Arginase by N ω-Hydroxy-l-Arginine Controls the Growth of Leishmania Inside Macrophages , 2001, The Journal of experimental medicine.

[35]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[36]  P. De Baetselier,et al.  Alternative versus classical macrophage activation during experimental African trypanosomosis , 2001, International journal for parasitology.

[37]  A. Casadevall,et al.  Cryptococcus neoformans Is a Facultative Intracellular Pathogen in Murine Pulmonary Infection , 2000, Infection and Immunity.

[38]  Constantin E. Orfanos,et al.  Alternative versus Classical Activation of Macrophages , 2000, Pathobiology.

[39]  A. Casadevall,et al.  Phenotypic Switching in Cryptococcus neoformansResults in Changes in Cellular Morphology and Glucuronoxylomannan Structure , 1999, Infection and Immunity.

[40]  A. Casadevall,et al.  Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  F. Bistoni,et al.  Encapsulation of Cryptococcus neoformans with Glucuronoxylomannan Inhibits the Antigen-Presenting Capacity of Monocytes , 1998, Infection and Immunity.

[42]  A. Casadevall,et al.  Microevolution of a Standard Strain ofCryptococcus neoformans Resulting in Differences in Virulence and Other Phenotypes , 1998, Infection and Immunity.

[43]  F. Dromer,et al.  Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). French Cryptococcosis Study Group. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  T. G. Mitchell,et al.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans , 1995, Clinical microbiology reviews.

[45]  M. Modolell,et al.  Determination of arginase activity in macrophages: a micromethod. , 1994, Journal of immunological methods.

[46]  N. Van Rooijen,et al.  Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. , 1994, Journal of immunological methods.

[47]  K. Kawakami,et al.  Activation of macrophages and expansion of specific T lymphocytes in the lungs of mice intratracheally inoculated with Cryptococcus neoformans , 1994, Clinical and experimental immunology.

[48]  G. Huffnagle,et al.  The role of CD4+ and CD8+ T cells in the protective inflammatory response to a pulmonary cryptococcal infection , 1994, Journal of leukocyte biology.

[49]  A. Luca,et al.  IL-17 and Therapeutic Kynurenines in Pathogenic Inflammation to Fungi , 2008 .

[50]  S. Gordon.  Alternative activation of macrophages , 2003, Nature Reviews Immunology.

[51]  S. Levitz.  Macrophage-Cryptococcus interactions. , 1994, Immunology series.